CLINICAL TRIALS PROFILE FOR NUTRACORT

All Clinical Trials for NUTRACORT

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT01867294 ↗	Spironolactone in Preventing Rash in Patients With Advanced Cancer Receiving Panitumumab and Cetuximab	Completed	National Cancer Institute (NCI)	Phase 2	2012-08-31	This randomized phase II trial studies how well giving spironolactone works in preventing rash in patients with cancer that has spread to other places in the body and are receiving panitumumab and cetuximab. Spironolactone may prevent endothelial growth factor receptor (EGFR) inhibitor-induced skin rash.
NCT00557193 ↗	Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia	Active, not recruiting	National Cancer Institute (NCI)	Phase 3	2008-01-14	This phase III trial studies combination chemotherapy with or without lestaurtinib with to see how well they work in treating younger patients with newly diagnosed acute lymphoblastic leukemia. Drugs used in chemotherapy work in different ways to stop the growth of stop cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Lestaurtinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. It is not yet known whether combination chemotherapy is more effective with or without lestaurtinib in treating acute lymphoblastic leukemia.
NCT00557193 ↗	Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia	Active, not recruiting	Children's Oncology Group	Phase 3	2008-01-14	This phase III trial studies combination chemotherapy with or without lestaurtinib with to see how well they work in treating younger patients with newly diagnosed acute lymphoblastic leukemia. Drugs used in chemotherapy work in different ways to stop the growth of stop cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Lestaurtinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. It is not yet known whether combination chemotherapy is more effective with or without lestaurtinib in treating acute lymphoblastic leukemia.
NCT00536991 ↗	Calcitriol in Combination With Ketoconazole and Therapeutic Hydrocortisone in Treating Patients With Prostate Cancer	Terminated	National Cancer Institute (NCI)	Phase 1/Phase 2	2006-10-01	This phase I/II trial studies the side effects and best dose of calcitriol when given in combination with ketoconazole and therapeutic hydrocortisone and to see how well it works in treating patients with prostate cancer. Calcitriol may help prostate cancer cells become more like normal cells and grow and spread more slowly. Ketoconazole and therapeutic hydrocortisone may help calcitriol work better by making tumor cells more sensitive to the drug. Giving calcitriol together with ketoconazole and therapeutic hydrocortisone may be a better treatment for prostate cancer.
NCT00536991 ↗	Calcitriol in Combination With Ketoconazole and Therapeutic Hydrocortisone in Treating Patients With Prostate Cancer	Terminated	Roswell Park Cancer Institute	Phase 1/Phase 2	2006-10-01	This phase I/II trial studies the side effects and best dose of calcitriol when given in combination with ketoconazole and therapeutic hydrocortisone and to see how well it works in treating patients with prostate cancer. Calcitriol may help prostate cancer cells become more like normal cells and grow and spread more slowly. Ketoconazole and therapeutic hydrocortisone may help calcitriol work better by making tumor cells more sensitive to the drug. Giving calcitriol together with ketoconazole and therapeutic hydrocortisone may be a better treatment for prostate cancer.

Clinical Trial Conditions for NUTRACORT

Condition Name

Condition Name for NUTRACORT
Intervention	Trials
Untreated Childhood Acute Lymphoblastic Leukemia	2
B Acute Lymphoblastic Leukemia	2
Acute Lymphoblastic Leukemia	2
Blasts 5 Percent or More of Bone Marrow Nucleated Cells	1

Condition MeSH

Condition MeSH for NUTRACORT
Intervention	Trials
Leukemia	4
Leukemia, Lymphoid	3
Precursor Cell Lymphoblastic Leukemia-Lymphoma	3
Leukemia, Myeloid, Acute	2

Clinical Trial Locations for NUTRACORT

Trials by Country

+

−

Trials by Country for NUTRACORT
Location	Trials
United States	213
Canada	30
Australia	5
New Zealand	5
Puerto Rico	3

Trials by US State

+

−

Trials by US State for NUTRACORT
Location	Trials
Illinois	7
Minnesota	6
Massachusetts	6
Wisconsin	6
New York	6

Clinical Trial Progress for NUTRACORT

Clinical Trial Phase

Clinical Trial Phase for NUTRACORT
Clinical Trial Phase	Trials
Phase 3	4
Phase 2	1
Phase 1/Phase 2	2

Clinical Trial Status

Clinical Trial Status for NUTRACORT
Clinical Trial Phase	Trials
Active, not recruiting	4
Recruiting	2
Completed	1

Clinical Trial Sponsors for NUTRACORT

Sponsor Name

Sponsor Name for NUTRACORT
Sponsor	Trials
National Cancer Institute (NCI)	8
Children's Oncology Group	4
Millennium Pharmaceuticals, Inc.	1

Sponsor Type

Sponsor Type for NUTRACORT
Sponsor	Trials
NIH	8
Other	8
Industry	1

Clinical Trials, Market Analysis, and Projections for Nutracort

Introduction to Nutracort

Nutracort, a formulation of hydrocortisone, is a corticosteroid used for various medical conditions, including skin allergies, asthma, and other inflammatory diseases. To understand the current and future landscape of Nutracort, it is essential to delve into clinical trials, market analysis, and projections.

Clinical Trials Overview

Historical Context and Success Rates

Clinical trials for drugs like Nutracort involve multiple phases, each with its own success rates. A comprehensive analysis of clinical trials from 2000 to 2015 shows that the overall success rates for drugs vary significantly by therapeutic area. For example, in the autoimmune/inflammation category, which includes drugs like Nutracort, the success rates from Phase 1 to Phase 2, Phase 2 to Phase 3, and Phase 3 to approval are around 26.3%, 16.2%, and 33.6% respectively, without the use of biomarkers[1].

Role of Biomarkers

The use of biomarkers can significantly improve the success rates of clinical trials. For instance, trials using biomarkers in the oncology sector have shown higher success rates compared to those without biomarkers. This trend suggests that incorporating biomarkers in the development of Nutracort or similar drugs could enhance their efficacy and approval rates[1].

Specific Trials for Nutracort

While specific data on Nutracort trials is not extensively detailed in the available sources, the general trends in clinical trials for corticosteroids indicate a rigorous evaluation process. These trials typically assess the drug's efficacy, safety, and optimal dosage across various patient populations.

Market Analysis

Current Market Size and Growth

The nutraceuticals market, which includes products like Nutracort, is experiencing robust growth. In 2023, the global nutraceuticals market was valued at USD 317.2 billion and is projected to reach USD 599.7 billion by 2030, growing at a CAGR of 9.5% from 2023 to 2030[5].

Segment Performance

Within the nutraceuticals market, the probiotics segment is the largest and fastest-growing, but other segments such as dietary supplements and functional foods also contribute significantly. Nutracort, as a hydrocortisone formulation, falls under the dietary supplements or pharmaceuticals segment, which is expected to see substantial growth driven by increasing consumer awareness of health benefits and rising chronic disease prevalence[2][5].

Regional Market Dynamics

The Asia Pacific region is anticipated to be the fastest-growing market for nutraceutical products, including those like Nutracort. Factors such as busy lifestyles, economic development, and increased demand for fortified nutritional products drive this growth. North America and Europe also represent significant markets, with steady growth rates expected over the forecast period[2][5].

Market Projections

Growth Drivers

Several factors are driving the growth of the market for products like Nutracort:

• Increasing Geriatric Population: An aging population is more prone to chronic diseases, increasing the demand for health supplements and pharmaceuticals.
• Rising Prevalence of Chronic Diseases: Conditions such as allergies, asthma, and other inflammatory diseases are on the rise, necessitating more treatments like Nutracort.
• Heightened Consumer Awareness: Consumers are becoming more aware of the health benefits of nutraceutical products, leading to increased demand[2].

Market Segments and Channels

The food segment, including protein-rich snacks and nutritional bars, is expected to command a significant share of the nutraceutical market. Specialty stores are also projected to witness high growth, although conventional stores will maintain the largest market share during the forecast period[2].

Side Effects and Safety Considerations

Common and Severe Side Effects

Nutracort, being a hydrocortisone formulation, can have various side effects, including:

• Dermatologic: Acne, allergic dermatitis, dry scaly skin, and thin fragile skin.
• Metabolic: Fluid retention, hypokalemic alkalosis, and weight gain.
• Respiratory: Pulmonary edema (frequency not reported)[4].

Clinical Implications

Understanding these side effects is crucial for clinicians and patients to manage treatment effectively. The balance between therapeutic efficacy and potential side effects is a key consideration in clinical trials and post-market surveillance.

Key Takeaways

• Clinical Trials Success Rates: The use of biomarkers can enhance the success rates of clinical trials for drugs like Nutracort.
• Market Growth: The nutraceuticals market, including products like Nutracort, is expected to grow significantly, driven by increasing consumer awareness and rising chronic disease prevalence.
• Regional Dynamics: The Asia Pacific region is poised for the fastest growth, while North America and Europe will also see substantial market expansion.
• Side Effects and Safety: Understanding the potential side effects of Nutracort is essential for effective treatment management.

FAQs

What is the current market size of the nutraceuticals industry?

The global nutraceuticals market was valued at USD 317.2 billion in 2023[5].

What is the projected growth rate of the nutraceuticals market from 2023 to 2030?

The market is expected to grow at a CAGR of 9.5% from 2023 to 2030[5].

Which segment is the largest and fastest-growing in the nutraceuticals market?

The probiotics segment is both the largest and the fastest-growing segment in the nutraceuticals market[5].

What are some common side effects of Nutracort?

Common side effects include dermatologic issues like acne and dry scaly skin, metabolic issues like fluid retention, and respiratory issues like pulmonary edema[4].

How does the use of biomarkers impact clinical trial success rates?

The use of biomarkers can significantly improve the success rates of clinical trials by better identifying therapeutic efficacy and toxicity, as well as patient stratification[1].

Which region is expected to see the fastest growth in the nutraceuticals market?

The Asia Pacific region is anticipated to be the fastest-growing market for nutraceutical products[2].